Soleno Therapeutics

SLNO

Market cap $2.71B

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEWTOWN, Pa., Nov. 16, 2025 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Soleno Therapeutics, Inc. (“Soleno” or “the Company”) (NASDAQ: SLNO), resulting from allegations of providing potentially misleading business information to the investing public.

SAN DIEGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Soleno Therapeutics, Inc. (NASDAQ: SLNO) focused on whether Soleno and certain of its executives made false and/or misleading statements and/or failed to disclose material information to investors.

SAN FRANCISCO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) saw the price of their shares tumble $18.78 (-28%) after the company reported disappointing information about VYKAT™ XR, a once-daily oral tablet intended to treat hyperphagia. Soleno has described this condition as "the most life-limiting aspect" of Prader-Willi syndrome, a rare genetic disorder that causes physical, mental, and behavioral problems.

LOS ANGELES, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Soleno Therapeutics, Inc., (“Soleno" or the "Company") (NASDAQ: SLNO) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Soleno Therapeutics, Inc. (NASDAQ: SLNO) or certain of its officers and directors violated federal securities laws by making false or misleading statements and/or failing to disclose material information to investors.

REDWOOD CITY, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that its Board of Directors has authorized a share repurchase and that it has entered into an Accelerated Share Repurchase Agreement (“ASR”) with Jefferies LLC (“Jefferies”) to repurchase $100 million of Soleno's common stock.

SAN DIEGO--(BUSINESS WIRE)--This is an is investigation into potential violations of U.S. federal securities laws involving Soleno Therapeutics, Inc.

NEWTOWN, Pa. , Nov. 10, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO), resulting from allegations of providing potentially misleading business information to the investing public.

SAN DIEGO , Nov. 7, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Soleno Therapeutics, Inc. (NASDAQ: SLNO) focused on whether Soleno and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Soleno investigation or if you are a Soleno investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-soleno-therapeutics-inc-investigation-slno.html You can also contact attorneys J.C.